Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis
Vincent Ribrag(Institut Gustave Roussy), Gilles Salles(Université Claude Bernard Lyon 1)
Cited by 39
Related Papers
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
Primary breast lymphoma: a report of 20 cases
|British Journal of Haematology|2001|100